|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07J 9/00 | (2006.01) |
| A61K 31/575 | (2006.01) | ||
| C07J 31/00 | (2006.01) | ||
| A61P 1/16 | (2006.01) |
| (11) | Number of the document | 2040713 |
| (13) | Kind of document | T |
| (96) | European patent application number | 07809913.2 |
| Date of filing the European patent application | 2007-06-27 | |
| (97) | Date of publication of the European application | 2009-04-01 |
| (45) | Date of publication and mention of the grant of the patent | 2014-06-18 |
| (46) | Date of publication of the claims translation | 2014-11-25 |
| (86) | Number | PCT/US2007/014829 |
| Date | 2007-06-27 |
| (87) | Number | WO 2008/002573 |
| Date | 2008-01-03 |
| (30) | Number | Date | Country code |
| 816635 P | 2006-06-27 | US |
| (72) |
PELLICCIARI, Roberto, IT
FIORUCCI, Stefano, IT
PRUZANSKI, Mark, US
|
| (73) |
Intercept Pharmaceuticals Inc.,
421 Hudson Street, Suite 212, New York, New York 10014,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Tulžies rūgšties dariniai, kaip FRX ligandai, skirti FRX medijuojamų ligų arba būklių prevencijai arba gydymui |
| BILE ACID DERIVATIVES AS FXR LIGANDS FOR THE PREVENTION OR TREATMENT OF FXR-MEDIATED DESEASES OR CONDITIONS |
| Payment date | Validity (years) | Amount | |
| 2021-06-02 | 15 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2022-06-27 |